Why investing in CUTISS AG

CUTISS is a biotech spin-off of from the University of Zurich (UZH), and we have an ambitious vision. We want to give patients back more of their own, healthy skin to make them well again. 

Our knowledge in skin bioengineering, pigmentation and biology offers several growth opportunities in regenerative medicine, as well as in fields beyond medicine.

We are specialized in the development of personalized, biotechnological skin transplantation products for the treatment of burns, skin defects and extensive scar corrections.

Our lead product is denovoSkin which has successfully completed Phase I in pediatric patients. Phase II clinical trials are underway in Europe and Switzerland and clinical outcome data is expected to become available in 2023.

The company is also working on the scale-up of production through automation. We have developed our own unique approach to bioengineering human skin tissue composed of three modules: cell isolation (Semotiss™), cell expansion (Quantum®), and skin tissue formation (denovoCast™). Starting form a patient’s biopsy and working in sequence, the modules produce the personalized skin graft denovoSkin™.

CUTISS has signed an exclusive licensing agreement for the commercialization of VitiCell® worldwide, a CE marked medical device developed by IBSA for the treatment of skin pigmentation disorders. Vitiligo is the most common skin pigmentation disorder with approximately 1-2% of the global population affected. Patients with stable Vitiligo and post-traumatic scars are eligible for treatment with VitiCell®. CUTISS will actively commercialize VitiCell® once the device’s existing EU MDD license is converted to the EU MDR license.

We are looking for new investors with a long-term strategy and a focus on innovation in Life Sciences.

Investors to date have included, among others, Giammaria Giuliani of Giuliani Pharma, Zürcher Kantonalbank (ZKB), the Wyss Foundation and Yellowstone Holding; CUTISS AG also received funds granted from the European Union (H2020 program), Innosuisse and Wyss Zurich.

For more information, please contact our CEO, Dr. Daniela Marino.

Investors already include:

Scroll to Top


Would you like to contact us as a journalist?


This website uses cookies to ensure you get the best experience on our website.